The Economic Burden of Schizophrenia in the United States in 2002
about
Peer support for schizophreniaCan the Direct Medical Cost of Chronic Disease Be Transferred across Different Countries? Using Cost-of-Illness Studies on Type 2 Diabetes, Epilepsy and Schizophrenia as ExamplesSynchronizing theta oscillations with direct-current stimulation strengthens adaptive control in the human brainEfficacy and safety of pharmacological and psychological interventions for the treatment of psychosis and schizophrenia in children, adolescents and young adults: a systematic review and meta-analysisPostmortem brain: an underutilized substrate for studying severe mental illness[Calculation of disease-related costs in claims data analyses with the example of attention-deficit hyperactivity disorder. Comparison of methods].Resource utilization in patients with schizophrenia who initiated risperidone long-acting therapy: results from the Schizophrenia Outcomes Utilization Relapse and Clinical Evaluation (SOURCE).Genetics of antipsychotic treatment emergent weight gain in schizophrenia.The puzzle of schizophrenia: tracking the core role of cognitive deficits.Involvement in the US criminal justice system and cost implications for persons treated for schizophrenia.Acceptance and Commitment Therapy for Inpatients with Psychosis (the REACH Study): Protocol for Treatment Development and Pilot Testing.Change in level of productivity in the treatment of schizophrenia with olanzapine or other antipsychoticsAssessment of effectiveness measures in patients with schizophrenia initiated on risperidone long-acting therapy: the SOURCE study resultsCost-effectiveness analysis of psychosocial intervention for early stage schizophrenia in China: a randomized, one-year study.Comprehensive gene-based association study of a chromosome 20 linked region implicates novel risk loci for depressive symptoms in psychotic illness.Efficacy and tolerability of quetiapine versus haloperidol in first-episode schizophrenia: a randomized clinical trial.The role of long-acting injectable antipsychotics in schizophrenia: a critical appraisal.Antipsychotic Maintenance Treatment: Time to Rethink?Long-term healthcare costs and functional outcomes associated with lack of remission in schizophrenia: a post-hoc analysis of a prospective observational studyReducing the duration of untreated psychosis and its impact in the U.S.: the STEP-ED studyClinical and functional outcomes after 2 years in the early detection and intervention for the prevention of psychosis multisite effectiveness trial.Impact of atypical long-acting injectable versus oral antipsychotics on rehospitalization rates and emergency room visits among relapsed schizophrenia patients: a retrospective database analysisPredictors of psychiatric hospitalization during 6 months of maintenance treatment with olanzapine long-acting injection: post hoc analysis of a randomized, double-blind studyAntipsychotic adherence patterns and health care utilization and costs among patients discharged after a schizophrenia-related hospitalizationStrategies for effective recruitment of individuals at risk for developing psychosisThe cost of inpatient care of schizophrenia in the Polish and Ukrainian academic centers--Poznan and LvivHealth care resource utilization and direct medical costs for patients with schizophrenia initiating treatment with atypical versus typical antipsychotics in Tianjin, China.The Early Psychosis Intervention Center (EPICENTER): development and six-month outcomes of an American first-episode psychosis clinical service.Induced pluripotent stem cells in the study of neurological diseases.Correlates of schizophrenia spectrum disorders in children and adolescents cared for in community settings.The Promises and Challenges of Ecological Momentary Assessment in Schizophrenia: Development of an Initial Experimental ProtocolEstimated economic benefits from low-frequency administration of atypical antipsychotics in treatment of schizophrenia: a decision model.Lurasidone in the treatment of schizophrenia: a 6-week, placebo-controlled study.Affect recognition deficits in schizophrenia: neural substrates and psychopharmacological implications.Recent developments in psychosocial treatments for schizophrenic patients.When functional capacity and real-world functioning converge: the role of self-efficacy.Transcriptome study of differential expression in schizophrenia.An investigation of economic costs of schizophrenia in two areas of China.Identifying phenotypic signatures of neuropsychiatric disorders from electronic medical records.Metabolic Abnormalities in the Hippocampus of Patients with Schizophrenia: A 3D Multivoxel MR Spectroscopic Imaging Study at 3T.
P2860
Q24202186-27EE6E10-5464-4A5F-9F93-F802DD9957EBQ26774170-0A0C8C62-73EA-46D3-8681-815D98E9EDD4Q27323969-34C51DE4-A7A0-42D1-BE0E-C9E4E2CEDEFBQ28650054-23533A2C-96E7-47B8-8E25-89081166B9A6Q30422050-81A50D69-254C-488F-8CBD-DC334191E06BQ30596477-9158CED5-EF28-4EC2-9B2B-2B6284BB9754Q31038656-BEC377BE-1984-4658-BD78-4A7C046B6356Q33257886-E0167CC8-F310-4A1C-B84B-EDA660159085Q33353490-3527874D-5082-4365-8E32-078140B09856Q33527102-A3CA8ADE-9F64-490E-B227-7C6A6CA4F75EQ33855985-DC868EF3-CEFF-4790-A27B-655E52180296Q33903511-52918076-6CA5-4CF4-B4AD-168F6F01CFA9Q34048194-AB542E1F-4647-4A59-8DFD-4FF9D416B63BQ34109190-D0850122-10C8-4CA7-BEF2-E266D318691FQ34119018-6C355E45-A9FD-4BAC-B604-6CD482A17F81Q34242783-87FDC1F8-D30F-486D-89FF-7E951D3DAB0DQ34418847-D9B027B3-2522-4A62-A434-AB381AC2F9EDQ34488215-A04EC298-CAAA-4F11-9024-7496E1F3D83CQ34502693-A4F049BA-9B5C-46EC-BB43-C8EB0652B1FFQ34672429-6FCE1084-E04D-4DC2-B645-874CB657374CQ34701054-94B1E652-626C-4295-813B-BCFCFB55CCC7Q34982167-9C7965CE-B63B-4989-842F-193E78F409E4Q34990923-968CBA15-FCF3-4244-9612-8ABE852F0448Q35008229-50669A24-BC0E-4E9F-B78C-3343F58CE982Q35132114-3B151AA3-C63D-4B45-A617-D902790357EFQ35182685-C4ADCE92-050E-4E22-A389-167FBFABFC7AQ35568945-7CEF3A82-1B2D-4325-BB21-8FE9D8E54A2CQ35825226-A19B835E-9214-47CA-9202-3C91C933F742Q35840653-FD9A621A-9F83-4D58-8EA5-0F2173F04FBEQ35949642-AB438726-42B9-4E70-850D-94537848E6F6Q36383958-4761FFCB-7BAC-4CD3-8AAD-646C9098383DQ36445106-513C02B2-01D1-40A0-83CF-61BC4ED402F9Q36537114-562611E8-4DA9-4311-8195-107BA83EEB33Q36870052-0AE203FC-46F8-4B61-8ED6-310761C357A4Q36870058-027733CD-90F6-4E3E-8446-B791EDB5E065Q36940002-A8E4926E-A2F3-4658-A740-8A716CE28D4CQ37332227-C951AF68-EA0F-41F0-BA19-888D72492167Q37350099-59C3F5D7-EC27-4F2A-810D-4B8682C9E4C5Q37389419-9EA486E9-A185-4001-BB66-EEA7C60BA62AQ37510500-7EB8DDFE-33F4-4E39-B0F1-CE8E492C2686
P2860
The Economic Burden of Schizophrenia in the United States in 2002
description
2005 nî lūn-bûn
@nan
2005 թուականի Սեպտեմբերին հրատարակուած գիտական յօդուած
@hyw
2005 թվականի սեպտեմբերին հրատարակված գիտական հոդված
@hy
2005年の論文
@ja
2005年論文
@yue
2005年論文
@zh-hant
2005年論文
@zh-hk
2005年論文
@zh-mo
2005年論文
@zh-tw
2005年论文
@wuu
name
The Economic Burden of Schizophrenia in the United States in 2002
@ast
The Economic Burden of Schizophrenia in the United States in 2002
@en
The Economic Burden of Schizophrenia in the United States in 2002
@en-gb
type
label
The Economic Burden of Schizophrenia in the United States in 2002
@ast
The Economic Burden of Schizophrenia in the United States in 2002
@en
The Economic Burden of Schizophrenia in the United States in 2002
@en-gb
prefLabel
The Economic Burden of Schizophrenia in the United States in 2002
@ast
The Economic Burden of Schizophrenia in the United States in 2002
@en
The Economic Burden of Schizophrenia in the United States in 2002
@en-gb
P2093
P356
P1476
The Economic Burden of Schizophrenia in the United States in 2002
@en
P2093
Daniel E. Ball
Howard G. Birnbaum
Jyoti Aggarwal
Lizheng Shi
Matthew Moulis
P304
P356
10.4088/JCP.V66N0906
P577
2005-09-15T00:00:00Z